Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044577 · ClinicalTrials.gov registry record · Phase 3
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
A Phase 3 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 166
- Enrollment target
NCT00044577 is a Phase 3 study that has completed, run by ViiV Healthcare. The registered enrollment target is 166 participants.
The verdict
NCT00044577, a Phase 3 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 166 participants
- Enrollment target
Study Summary
A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.
Interventions
- DRUG lamivudine
- DRUG tenofovir
- DRUG abacavir/lamivudine
- DRUG abacavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2002-07-16 |
| Est. Completion | 2004-05-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044577
The ClinicalTrials.gov registry entry for NCT00044577 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which lamivudine is the first listed.
NCT00044577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044577 about?
NCT00044577 is a clinical study titled "New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects". A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.
What is the current status of trial NCT00044577?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 166 participants. The study started on 2002-07-16. Estimated completion is 2004-05-25.
What interventions are being tested in trial NCT00044577?
The interventions under investigation include: lamivudine (DRUG), tenofovir (DRUG), abacavir/lamivudine (DRUG), abacavir (DRUG).
Who is sponsoring clinical trial NCT00044577?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.